Inherited forms of mineralocorticoid hypertension

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 29, Issue 4, 2015, Pages 633-645

  Zennaro, Maria Christina ^a,b,c   Boulkroun, Sheerazed ^a,b   Fernandes Rosa, Fabio ^a,b,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

11 hydroxysteroid dehydrogenase; apparent mineralocorticoid excess; congenital adrenal hyperplasia; epithelial sodium channel; familial hyperkalemic hypertension; mineralocorticoid receptor; primary aldosteronism

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID RECEPTOR; RENIN; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CONGENITAL ADRENAL HYPERPLASIA; DISEASE CLASSIFICATION; DISORDERS OF STEROID METABOLISM; ENZYME DEFICIENCY; FAMILIAL HYPERALDOSTERONISM TYPE 1; FAMILIAL HYPERALDOSTERONISM TYPE II; FAMILIAL HYPERALDOSTERONISM TYPE III; FAMILIAL HYPERKALEMIC HYPERTENSION; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; HUMAN; LIDDLE SYNDROME; ONSET AGE; PRIMARY HYPERALDOSTERONISM; COMPLICATION; GENETICS; HYPERALDOSTERONISM; HYPERTENSION; METABOLISM; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; MUTATION;

HUMANS; HYPERALDOSTERONISM; HYPERTENSION; LIDDLE SYNDROME; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; MUTATION;

EID: 84940438943     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2015.04.010     Document Type: Review

References (100)

1. M.C. Zennaro, A.J. Rickard, and S. Boulkroun Genetics in endocrinology: genetics of mineralocorticoid excess: an update for clinicians Eur J Endocrinol 169 2013 R15 R25
2. V. Campean, J. Kricke, D. Ellison, and et al. Localization of thiazide-sensitive Na(+)-Cl(-) cotransport and associated gene products in mouse DCT Am J Physiol Ren Physiol 281 2001 F1028 F1035
3. J. Loffing, D. Loffing-Cueni, V. Valderrabano, and et al. Distribution of transcellular calcium and sodium transport pathways along mouse distal nephron Am J Physiol Ren Physiol 281 2001 F1021 F1027
4. Nuclear Receptors Nomenclature C A unified nomenclature system for the nuclear receptor superfamily Cell 97 1999 161 163
5. J.D. Stockand New ideas about aldosterone signaling in epithelia Am J Physiol Ren Physiol 282 2002 F559 F576
6. V. Bhalla, R. Soundararajan, A.C. Pao, and et al. Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ Am J Physiol Ren Physiol 291 2006 F714 F721
7. R. Soundararajan, T.T. Zhang, J. Wang, and et al. A novel role for glucocorticoid-induced leucine zipper protein in epithelial sodium channel-mediated sodium transport J Biol Chem 280 2005 39970 39981
8. F. Verrey, P. Fakitsas, G. Adam, and et al. Early transcriptional control of ENaC (de)ubiquitylation by aldosterone Kidney Int 73 2008 691 696
9. W.H. Wang, P. Yue, P. Sun, and et al. Regulation and function of potassium channels in aldosterone-sensitive distal nephron Curr Opin Nephrol Hypertens 19 2010 463 470
10. A.M. Ring, Q. Leng, J. Rinehart, and et al. An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis Proc Natl Acad Sci U. S. A 104 2007 4025 4029
11. V. Vallon, P. Wulff, D.Y. Huang, and et al. Role of Sgk1 in salt and potassium homeostasis Am J Physiol Regul Integr Comp Physiol 288 2005 R4 R10
12. C.A. Wagner, J. Kovacikova, P.A. Stehberger, and et al. Renal acid-base transport: old and new players Nephron Physiol 103 2006 p1 6
13. D. Bacic, P. Capuano, M. Baum, and et al. Activation of dopamine D1-like receptors induces acute internalization of the renal Na+/phosphate cotransporter NaPi-IIa in mouse kidney and OK cells Am J Physiol Ren Physiol 288 2005 F740 F747
14. C. Winter, N. Schulz, G. Giebisch, and et al. Nongenomic stimulation of vacuolar H+-ATPases in intercalated renal tubule cells by aldosterone Proc Natl Acad Sci U. S. A 101 2004 2636 2641
15. J. Loffing, and B. Kaissling Sodium and calcium transport pathways along the mammalian distal nephron: from rabbit to human Am J Physiol Ren Physiol 284 2003 F628 F643
16. M. Bostanjoglo, W.B. Reeves, R.F. Reilly, and et al. 11Beta-hydroxysteroid dehydrogenase, mineralocorticoid receptor, and thiazide-sensitive Na-Cl cotransporter expression by distal tubules J Am Soc Nephrol 9 1998 1347 1358
17. N. Farman, and M.E. Rafestin-Oblin Multiple aspects of mineralocorticoid selectivity Am J Physiol Ren Physiol 280 2001 F181 F192
18. J.M. Connell, and E. Davies The new biology of aldosterone J Endocrinol 186 2005 1 20
19. A. Spat, and L. Hunyady Control of aldosterone secretion: a model for convergence in cellular signaling pathways Physiol Rev 84 2004 489 539
20. C. Newton-Cheh, C.Y. Guo, P. Gona, and et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample Hypertension 49 2007 846 856
21. R.S. Vasan, J.C. Evans, M.G. Larson, and et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons N. Engl J Med 351 2004 33 41
22. P. Meneton, P. Galan, S. Bertrais, and et al. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations J Hum Hypertens 22 2008 550 558
23. A. Hannemann, and H. Wallaschofski Prevalence of primary aldosteronism in patient's cohorts and in population-based studies-a review of the current literature Horm Metab Res 44 2012 157 162
24. D.A. Calhoun, M.K. Nishizaka, M.A. Zaman, and et al. Hyperaldosteronism among black and white subjects with resistant hypertension Hypertension 40 2002 892 896
25. D.J. Sutherland, J.L. Ruse, and J.C. Laidlaw Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone Can Med Assoc J 95 1966 1109 1119
26. M. New Hypertension of childhood with suppressed renin Endocr Rev 1 1980 421 430
27. M. Aglony, A. Martinez-Aguayo, C.A. Carvajal, and et al. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation Hypertension 57 2011 1117 1121
28. R.P. Lifton, R.G. Dluhy, M. Powers, and et al. A chimaeric 11beta-hydroxylase aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension Nature 355 1992 262 265
29. M. Stowasser, and R.D. Gordon Primary aldosteronism: learning from the study of familial varieties J Hypertens 18 2000 1165 1176
30. R.V. Jackson, A. Lafferty, D.J. Torpy, and et al. New genetic insights in familial hyperaldosteronism Ann N. Y Acad Sci 970 2002 77 88
31. F. Pizzolo, E. Trabetti, P. Guarini, and et al. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting J Hum Hypertens 19 2005 325 327
32. P. Mulatero, D. Tizzani, A. Viola, and et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (primary aldosteronism in TOrino-GENetic forms) Hypertension 58 2011 797 803
33. R.G. Dluhy, and R.P. Lifton Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis Steroids 60 1995 48 51
34. W.R. Litchfield, B.F. Anderson, R.J. Weiss, and et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism Hypertension 31 1998 445 450
35. L.J. Gates, N. Benjamin, N.E. Haites, and et al. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 15 2001 173 176
36. J.W. Funder, R.M. Carey, C. Fardella, and et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline J Clin Endocrinol Metab 93 2008 3266 3281
37. C.E. Fardella, M. Pinto, L. Mosso, and et al. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene J Clin Endocrinol Metab 86 2001 4805 4807
38. M. Stowasser, A.W. Bachmann, P.R. Huggard, and et al. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension J Clin Endocrinol Metab 85 2000 3313 3318
39. M. Stowasser, J. Sharman, R. Leano, and et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I J Clin Endocrinol Metab 90 2005 5070 5076
40. S. Staermose, T.H. Marwick, R.D. Gordon, and et al. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1 Hypertension 53 2009 e31 32
41. M. Stowasser Update in primary aldosteronism J Clin Endocrinol Metab 94 2009 3623 3630
42. R.D. Gordon, M. Stowasser, T.J. Tunny, and et al. Clinical and pathological diversity of primary aldosteronism, including a new familial variety Clin Exp Pharmacol Physiol 18 1991 283 286
43. M. Stowasser, and R.D. Gordon Familial hyperaldosteronism J Steroid Biochem Mol Biol 78 2001 215 229
44. V. Medeau, G. Assie, M.C. Zennaro, and et al. Familial aspect of primary hyperaldosteronism: analysis of families compatible with primary hyperaldosteronism type 2 Ann Endocrinol Paris 66 2005 240 246
45. A. Pallauf, C. Schirpenbach, O. Zwermann, and et al. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience Horm Metab Res 44 2012 215 220
46. V. Medeau, G. Assié, M.-C. Zennaro, and et al. Familial aspects of primary aldosteronism: investigation of possible FH-2 families Ann Endocrinol 66 2005 1 7
47. A.R. Lafferty, D.J. Torpy, M. Stowasser, and et al. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22) J Med Genet 37 2000 831 835
48. A. So, D.L. Duffy, R.D. Gordon, and et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity J Hypertens 23 2005 1477 1484
49. N. Sukor, P. Mulatero, R.D. Gordon, and et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families J Hypertens 26 2008 1577 1582
50. A. So, Y.W. Jeske, R.D. Gordon, and et al. No evidence for coding region mutations in the retinoblastoma-associated Kruppel-associated box protein gene (RBaK) causing familial hyperaldosteronism type II Clin Endocrinol (Oxf) 65 2006 829 831
51. Y.W. Jeske, A. So, L. Kelemen, and et al. Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II Clin Exp Pharmacol Physiol 35 2008 380 385
52. D.M. Ballantine, S.A. Klemm, T.J. Tunny, and et al. PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas Clin Exp Pharmacol Physiol 23 1996 584 586
53. D.M. Ballantine, S.A. Klemm, T.J. Tunny, and et al. PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland Clin Exp Pharmacol Physiol 23 1996 582 583
54. E. Davies, A. Bonnardeaux, P.F. Plouin, and et al. Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma J Clin Endocrinol Metab 82 1997 611 615
55. P. Mulatero, P. Tauber, M.C. Zennaro, and et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism Hypertension 59 2012 235 240
56. D.S. Geller, J. Zhang, M.V. Wisgerhof, and et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism J Clin Endocrinol Metab 93 2008 3117 3123
57. M. Choi, U.I. Scholl, P. Yue, and et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension Science 331 2011 768 772
58. K. Oki, M. Plonczynski, M. Lam, and et al. The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line Endocrinology 153 2012 4328 4335
59. U.I. Scholl, C. Nelson-Williams, P. Yue, and et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5 Proc Natl Acad Sci U. S. A 109 2012 2533 2538
60. E. Charmandari, A. Sertedaki, T. Kino, and et al. A novel Point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension J Clin Endocrinol Metab 97 2012 E1532 E1539
61. S. Monticone, N.G. Hattangady, D. Penton, and et al. A Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III J Clin Endocrinol Metab 98 2013 E1861 E1865
62. M. Adachi, K. Muroya, Y. Asakura, and et al. Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature Hormone Res Paediatr 82 2014 138 142
63. D.S. Geller, A. Farhi, N. Pinkerton, and et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy [see comments] Science 289 2000 119 123
64. M.E. Rafestin-Oblin, A. Souque, B. Bocchi, and et al. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related Endocrinology 144 2003 528 533
65. M. Ramirez-Salazar, G. Romero-Gutierrez, S. Zaina, and et al. Relationship of aldosterone synthase gene (C-344T) and mineralocorticoid receptor (S810L) polymorphisms with gestational hypertension J Hum Hypertens 25 2011 320 326
66. F.H. Wilson, S. Disse-Nicodeme, K.A. Choate, and et al. Human hypertension caused by mutations in WNK kinases Science 293 2001 1107 1112
67. L.M. Boyden, M. Choi, K.A. Choate, and et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities Nature 482 2012 98 102
68. H. Louis-Dit-Picard, J. Barc, D. Trujillano, and et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron Nat Genet 44 2012 456 460 S451-3
69. L. Pintard, A. Willems, and M. Peter Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family EMBO J 23 2004 1681 1687
70. S. Bergaya, E. Vidal-Petiot, X. Jeunemaitre, and et al. Pathogenesis of pseudohypoaldosteronism type 2 by WNK1 mutations Curr Opin Nephrol Hypertens 21 2012 39 45
71. S. Shibata, J. Zhang, J. Puthumana, and et al. Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4 Proc Natl Acad Sci U. S. A 110 2013 7838 7843
72. J.A. McCormick, C.L. Yang, C. Zhang, and et al. Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3 J Clin Invest 124 2014 4723 4736
73. H. Mayan, I. Vered, M. Mouallem, and et al. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density J Clin Endocrinol Metab 87 2002 3248 3254
74. S.A. Sanjad, F.M. Mansour, R.H. Hernandez, and et al. Severe hypertension, hyperkalemia, and renal tubular acidosis responding to dietary sodium restriction Pediatrics 69 1982 317 324
75. M.I. New, L.S. Levine, E.G. Biglieri, and et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension J Clin Endocrinol Metab 44 1977 924 933
76. S. Ulick, L.S. Levine, P. Gunczler, and et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol J Clin Endocrinol Metab 49 1979 757 764
77. M.I. New, D.S. Geller, F. Fallo, and et al. Monogenic low renin hypertension Trends Endocrinol Metab 16 2005 92 97
78. B.S. Nunez, F.M. Rogerson, T. Mune, and et al. Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess Hypertension 34 1999 638 642
79. P.M. Stewart, A.M. Wallace, R. Valentino, and et al. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age Lancet 2 1987 821 824
80. S. Dave-Sharma, R.C. Wilson, M.D. Harbison, and et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess J Clin Endocrinol Metab 83 1998 2244 2254
81. Z. Hassan-Smith, and P.M. Stewart Inherited forms of mineralocorticoid hypertension Curr Opin Endocrinol Diabetes Obes 18 2011 177 185
82. A.S. Alzahrani, N. Aljuhani, E. Qasem, and et al. Apparent mineralocorticoid excess caused by a novel mutation in 11-beta hydroxysteroid dehydrogenase type 2 enzyme: its genetics and response to therapy Endocr Pract - Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 20 2014 e151 156
83. M. Palermo, M. Cossu, and C.H. Shackleton Cure of apparent mineralocorticoid excess by kidney transplantation N Engl J Med 339 1998 1787 1788
84. A.M. Khattab, C.H. Shackleton, B.A. Hughes, and et al. Remission of hypertension and electrolyte abnormalities following renal transplantation in a patient with apparent mineralocorticoid excess well documented throughout childhood J Pediatr Endocrinol Metab - JPEM 27 2014 17 21
85. G.W. Liddle, T. Bledsoe, and W. Coppage A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion Trans Assoc Am Phys 76 1963 199 213
86. M. Botero-Velez, J.J. Curtis, and D.G. Warnock Brief report: Liddle's syndrome revisited-a disorder of sodium reabsorption in the distal tubule N Engl J Med 330 1994 178 181
87. R.A. Schimkets, D.G. Warnock, C.M. Bositis, and et al. Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel Cell 79 1994 407 414
88. J.H. Hansson, C. Nelson-Williams, H. Suzuki, and et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome Nat Genet 11 1995 76 82
89. K.Q. Yang, Y. Xiao, T. Tian, and et al. Molecular genetics of Liddle's syndrome Clin Chim Acta - Int J Clin Chem 436 2014 202 206
90. K.K. Knight, D.R. Olson, R. Zhou, and et al. Liddle's syndrome mutations increase Na+ transport through dual effects on epithelial Na+ channel surface expression and proteolytic cleavage Proc Natl Acad Sci U. S. A 103 2006 2805 2808
91. H. Abriel, J. Loffing, J.F. Rebhun, and et al. Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome J Clin Invest 103 1999 667 673
92. S. Nimkarn, and M.I. New Steroid 11beta- hydroxylase deficiency congenital adrenal hyperplasia Trends Endocrinol Metab 19 2008 96 99
93. M. Zachmann, D. Tassinari, and A. Prader Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients J Clin Endocrinol Metab 56 1983 222 229
94. K. Joehrer, S. Geley, E.M. Strasser-Wozak, and et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency Hum Mol Genet 6 1997 1829 1834
95. M. Mimouni, H. Kaufman, A. Roitman, and et al. Hypertension in a neonate with 11 beta-hydroxylase deficiency Eur J Pediatr 143 1985 231 233
96. P.C. White, K.M. Curnow, and L. Pascoe Disorders of steroid 11 beta-hydroxylase isozymes Endocr Rev 15 1994 421 438
97. A. Rosler, E. Leiberman, J. Sack, and et al. Clinical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency Horm Res 16 1982 133 141
98. T. Yanase, E.R. Simpson, and M.R. Waterman 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition Endocr Rev 12 1991 91 108
99. R.J. Auchus The genetics, pathophysiology, and management of human deficiencies of P450c17 Endocrinol Metab Clin North Am 30 2001 101 119 vii
100. T. Yanase, M. Kagimoto, N. Matsui, and et al. Combined 17 alpha-hydroxylase/17,20-lyase deficiency due to a stop codon in the N-terminal region of 17 alpha-hydroxylase cytochrome P-450 Mol Cell Endocrinol 59 1988 249 253